Claims:

1. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, wherein:
i) said light chain variable amino acid sequence comprises SEQ ID NO: 127 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 126;
ii) said light chain variable amino acid sequence comprises SEQ ID NO: 140 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 131;
iii) said light chain variable amino acid sequence comprises SEQ ID NO: 141 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 133;
iv) said light chain variable amino acid sequence comprises SEQ ID NO: 142 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 133;
v) said light chain variable amino acid sequence comprises SEQ ID NO: 143 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 133;
vi) said light chain variable amino acid sequence comprises SEQ ID NO: 144 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 133;
vii) said light chain variable amino acid sequence comprises SEQ ID NO: 143 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 134;
viii) said light chain variable amino acid sequence comprises SEQ ID NO: 144 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 134;
ix) said light chain variable amino acid sequence comprises SEQ ID NO: 144 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 135;
x) said light chain variable amino acid sequence comprises SEQ ID NO: 143 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 132;
xi) said light chain variable amino acid sequence comprises SEQ ID NO: 139 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 129; or
xii) said light chain variable amino acid sequence comprises SEQ ID NO: 138 and said heavy chain variable amino acid sequence comprises SEQ ID NO: 130.

2. The isolated antibody according to claim 1(v), further comprising an IgG4 heavy chain constant region and an IgG4 light chain constant region optionally wherein the heavy chain

constant region comprises the amino acid sequence of SEQ ID NO:159 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:160.

3. An isolated nucleic acid molecule encoding the isolated human CD27 antibody or antigen-binding fragment thereof of any preceding claim 1 or 2, optionally selected from the group consisting of:

(i) a nucleotide sequence encoding the human CD27 antibody or antigen-binding fragment thereof of claim 1v;

(ii) the light chain nucleotide sequence of SEQ ID NO: 163 and/or the heavy chain nucleotide sequence of SEQ ID NO: 164; or

(iii) a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO: 143 and/or a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO: 133.

4. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule of claim 3.

5. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid vector or vectors of claim 4, optionally wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

6. A method for producing a CD27 antibody, comprising incorporating the nucleic acid molecule of claim 3 into a vector, transforming a host cell, transgenic animal or transgenic plant to express an antibody and recovering the expressed antibody.

7. An isolated human CD27 antibody or antigen-binding fragment thereof of any one of claims 1 or 2 for use in therapy.

8. Use of the isolated human CD27 antibody or antigen-binding fragment thereof of any one of claims 1 or 2, in the manufacture of a medicament for the treatment of a disorder in a subject in need thereof, wherein:

(i) the disorder is systemic lupus erythematosus; or

(ii) the disorder is selected from the group consisting of a disease of the pulmonary or pleural system, a disease of the central or peripheral nervous system, a disease of the eye or visual system, a disease of the gastrointestinal and digestive system, a disease of the cardiovascular system, an infectious disease, and a parasitic infection; and

wherein the antibody or antigen-binding fragment thereof is to be administered systemically to the subject.

9. The use of claim 8, wherein the medicament is for inhibiting naïve T-cell proliferation, wherein an effective amount of the antibody or antigen-binding fragment thereof is to be contacted with a tissue; and wherein the antibody or antigen-binding fragment thereof inhibits

the activation of CD27 on said human T-cells in the presence of human CD70 protein or a portion of human CD70 protein.

10. The use of claim 8, wherein the medicament is for inhibiting T-cell mediated B-cell antibody production, wherein an effective amount of the antibody or antigen-binding fragment thereof is to be contacted with a portion of the T-cells of the subject; and wherein the antibody or antigen-binding fragment thereof inhibits the activation of CD27 on said human T-cells in the presence of human CD70 protein or a portion of human CD70 protein.

11. An article of manufacture comprising a pharmaceutically acceptable formulation comprising the isolated human CD27 antibody or antigen-binding fragment thereof of any one of claims 1 or 2.